York Health Economics Consortium, Enterprise House, University of York, Innovation Way, York, YO10 5NQ, UK.
ALK Abelló, Horsholm, Denmark.
Qual Life Res. 2018 Sep;27(9):2383-2391. doi: 10.1007/s11136-018-1910-8. Epub 2018 Jun 8.
Allergic rhinitis and asthma symptoms are detrimental to health-related quality of life (HRQoL). Health technology appraisal agencies often require cost-utility analysis when assessing new interventions. Appropriate utility estimates, which quantify the value of different conditions in cost-utility analyses, are scarce for allergic rhinitis and asthma health states. This study aimed to generate utilities for allergic rhinitis and asthma health states from a European general population sample of adults and children.
Health state descriptions incorporating symptoms, impact of symptoms on daily life and symptom treatment were developed using clinical guidelines. Descriptions were amended with clinician and patient input, and incorporated into a survey in which each health state was followed by a standard gamble (adults) or visual analogue scale (children) item. The survey was distributed to samples of adults and children aged 8 to 11 from four European countries that were stratified to represent the general population within that country.
1454 adults and 1082 children completed the survey. Mean health utilities ranged from 0.635 to 0.880 and those elicited in children were lower (0.635 to 0.705) than those elicited in adults (0.812 to 0.880). Disutilities assessing the impact of increased allergic rhinitis severity and comorbidities were also greater in children than in adults.
Symptoms of allergic rhinitis and asthma were valued as having a clinically meaningful impact on HRQoL. Children valued health states as poorer than adults, and further research should investigate whether this reflects true preferential differences or results from methodological and/or comprehension differences between the two groups.
变应性鼻炎和哮喘症状对健康相关生活质量(HRQoL)有害。在评估新干预措施时,医疗技术评估机构通常需要进行成本效用分析。对于变应性鼻炎和哮喘健康状况,适当的效用估计(量化成本效用分析中不同状况的价值)非常稀缺。本研究旨在从欧洲成年人和儿童普通人群样本中生成变应性鼻炎和哮喘健康状况的效用。
使用临床指南制定了包含症状、症状对日常生活影响和症状治疗的健康状况描述。描述经过临床医生和患者的意见修改,并纳入一项调查中,其中每个健康状况后都有标准博弈(成年人)或视觉模拟量表(儿童)项目。该调查分发给来自四个欧洲国家的成年人和 8 至 11 岁儿童样本,这些样本分层代表该国的普通人群。
1454 名成年人和 1082 名儿童完成了调查。平均健康效用值范围为 0.635 至 0.880,儿童得出的效用值(0.635 至 0.705)低于成年人得出的效用值(0.812 至 0.880)。评估变应性鼻炎严重程度和合并症增加影响的不良效用在儿童中也大于成年人。
变应性鼻炎和哮喘的症状被认为对 HRQoL 具有临床意义的影响。儿童对健康状况的评价不如成年人,进一步的研究应该调查这是否反映了真正的偏好差异,还是由于两组之间的方法和/或理解差异造成的。